CAJ | 학술논문

目的探讨膀胱尿路上皮癌(BTCC)血浆及癌组织中单核细胞趋化蛋白1(MCP1)基因的表达与膀胱癌发病机制的相关性.方法 BTCC患者30例,男20例,女10例,分别取血浆和膀胱癌及癌旁组织标本.对照组为非肿瘤患者30例,男20例,女10例,取血液标本.酶联免疫吸附(ELISA)法测血浆中MCP1浓度,免疫组织化学SP法检测组织MCP1的表达情况.实时荧光定量PCR法检测MCP1mRNA表达水平.比较2组资料,分析膀胱癌临床特点与MCP1表达的关系.结果 BTCC组患者血浆中MCP1浓度为(193.4±105.7)pg/ml,高于非肿瘤组的(91.8±34.6)pg/ml(t=8.37,P＜0.001);BTCC组中浸润性患者MCP1血浆浓度为(204.3±167.5)pg/ml,高于表浅性患者的(130.6±69.2)pg/ml(t=2.667,P=0.013).免疫组织化学显示BTCC组织中MCP-1表达阳性率为70.0%(21/30),癌旁组织为43.3%(13/30),二者间差异有统计学意义(χ2=4.9,P＜0.05);BTCC组中浸润性者表达阳性率为80.0%(8/10),高于表浅性的65.0%(13/20).膀胱癌组织中MCP-1的阳性强度也明显高于对照组;BTCC组中浸润性者高于表浅性者.膀胱癌组织MCP-1总RNA和mRNA水平与对照组比较差异有统计学意义(χ2=10.08,P＜0.05).结论 MCP1基因表达上调可能在BTCC的发生及转移中发挥重要作用.
목적 탐토방광뇨로상피암(BTCC)혈장급암조직중단핵세포추화단백1(MCP1)기인적표체여방광암발병궤제적상관성.방법 BTCC환자30례,남20례,녀10례,분별취혈장화방광암급암방조직표본.대조조위비종류환자30례,남20례,녀10례,취혈액표본.매련면역흡부(ELISA)법측혈장중MCP1농도,면역조직화학SP법검측조직MCP1적표체정황.실시형광정량PCR법검측MCP1mRNA표체수평.비교2조자료,분석방광암림상특점여MCP1표체적관계.결과 BTCC조환자혈장중MCP1농도위(193.4±105.7)pg/ml,고우비종류조적(91.8±34.6)pg/ml(t=8.37,P＜0.001);BTCC조중침윤성환자MCP1혈장농도위(204.3±167.5)pg/ml,고우표천성환자적(130.6±69.2)pg/ml(t=2.667,P=0.013).면역조직화학현시BTCC조직중MCP-1표체양성솔위70.0%(21/30),암방조직위43.3%(13/30),이자간차이유통계학의의(χ2=4.9,P＜0.05);BTCC조중침윤성자표체양성솔위80.0%(8/10),고우표천성적65.0%(13/20).방광암조직중MCP-1적양성강도야명현고우대조조;BTCC조중침윤성자고우표천성자.방광암조직MCP-1총RNA화mRNA수평여대조조비교차이유통계학의의(χ2=10.08,P＜0.05).결론 MCP1기인표체상조가능재BTCC적발생급전이중발휘중요작용.
Objective To investigate the monocyte chemoattractant protein (MCP1) gene expression of the bladder urothelial carcinoma and its correlation with the pathogenesis of the bladder urothelial carcinoma.Methods Thirty cases of patients with the bladder urothelial carcinoma, including 20 cases of male and 10cases of female, were taken the blood and bladder tissue.In control group, 30 cases of non-cancer patients,including 20 cases of male and 10 cases of female, were taken the blood samples.ELISA method was used to detected the concentration of plasma MCP1, immunohistochemical method to investigate the expression of MCP1 in the bladder urothelial carcinoma and adjacent tissues.Real-time quantitative RT-PCR was applied to detected the expression of MCP1. Data of the two groups were comparied and the relationship between the expression of MCP1 and the clinical characteristics of the bladder urothelial carcinoma was analyzed.Results MCP1 in group of patients with the bladder urothelial carcinoma was (193.4±105.7) pg/ml, and higher than that in non-tumor group (91.8±34.6) pg/ml (t = 8.37, P ＜0.001).MCP1 in invasive bladder cancer was (204.3±167.5) pg/ml and superficial bladder cancer was (130.6±69.2) pg/ml (t = 2.667, P = 0.013). By immunohistochemistry, the MCP-1 positive rate in the bladder urothelial carcinoma was 70.0 % (21/30), that in adjacent cancer tissue was 43.3 % (13/30) (χ2 = 4.9, P ＜0.05). The positive rate of MCP1 in invasive bladder cancer in tumor group was 80.0 % (8/10) and that in superficial bladder cancer was 65.0 %(13/20).At the same time, MCP- 1 positive intensity in the bladder urothelial carcinoma was significantly higher than that in adjacent tissues. The intensity in invasive bladder cancer was higher than that in superficial ones. Total RNA and mRNA levels of MCP-1 in the bladder urothelial carcinoma were statistically differences compared with that in adjacent tissues (χ2 = 10.08, P ＜0.05).Conclusion The upregulation of MCP1 gene expression is likely to play an important role in the incidence and metastasis of the bladder urothelial carcinoma.